Jefferies analyst Matthew Stanton lowered the firm's price target on Azenta to $35 from $40 and keeps a Buy rating on the shares. The firm is updating its model for the recent acquisition of UK Biocentre, noting that the deal is expected to be dilutive to adjusted EBITDA pro-forma for fiscal year in 2026 and accretive to 2027/28 organic revenue growth and adjusted EBITDA margin.
